Stocktoria
PROTHENA CORP PUBLIC LTD CO PRTA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2012-12-21
PROTHENA CORP PUBLIC LTD CO financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.7M | $135.2M | $91.4M | $53.9M | $200.6M | $853,000 | $814,000 | $955,000 | $27.5M | $1.1M |
| R&D expense | $134.9M | $222.5M | $220.6M | $135.6M | $82.3M | $74.9M | $50.8M | $101.2M | $134.5M | $119.5M |
| Operating income | -$214.6M | -$154.6M | -$191.0M | -$131.6M | $72.0M | -$112.7M | -$85.7M | -$158.9M | -$155.3M | -$159.5M |
| Income tax | $43.3M | -$6.6M | -$13.5M | -$8.7M | $4.9M | -$283,000 | $379,000 | -$470,000 | -$4.4M | $1.1M |
| Net income | -$244.1M | -$122.3M | -$147.0M | -$116.9M | $67.0M | -$111.1M | -$77.7M | -$155.6M | -$153.2M | -$160.1M |
| EPS (diluted) | $-4.53 | $-2.27 | $-2.76 | $-2.47 | $1.38 | $-2.78 | $-1.95 | — | — | — |
| Operating cash flow | -$163.6M | -$150.1M | -$133.9M | -$108.8M | $92.6M | -$80.4M | -$53.0M | -$28.3M | -$131.2M | -$116.2M |
| Cash & equivalents | $307.5M | $471.4M | $618.8M | $710.4M | $579.1M | $295.4M | $375.7M | $427.7M | $417.6M | $386.9M |
| Total assets | $326.8M | $547.1M | $696.4M | $758.0M | $609.4M | $333.0M | $419.3M | $498.8M | $496.3M | $460.0M |
| Total liabilities | $46.3M | $60.2M | $135.0M | $136.0M | $143.3M | $149.0M | $146.3M | $175.8M | $89.1M | $94.6M |
| Shareholders' equity | $280.5M | $486.9M | $561.4M | $622.0M | $466.0M | $184.0M | $272.9M | $323.0M | $407.2M | $365.4M |
Growth · year-over-year · Revenue CAGR 27.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -92.8% | +47.9% | +69.5% | -73.1% | +23414.3% | +4.8% | -14.8% | -96.5% | +2508.4% | -34.3% |
| Net income growth | — | — | — | -274.6% | — | — | — | — | — | — |
| EPS growth | — | — | — | -279.0% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.